Journal: Structure (London, England : 1993)

Article Title: Structure of an RNA Aptamer that Can Inhibit HIV-1 by Blocking Rev-Cognate RNA (RRE) Binding and Rev-Rev Association

doi: 10.1016/j.str.2018.06.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: pET11a Rev 1–93 , Paul T. Wingfield (Genscript) , plasmid # 1979.

Techniques: Virus, Recombinant, Plasmid Preparation, Software, Control

Journal: Molecular Pharmacology

Article Title: The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray

doi: 10.1124/mol.115.099333

Figure Lengend Snippet: LPI elicits GPR55-mediated [Ca2+]i elevation of PAG neurons. (A) Typical tracings of the Ca2+ responses elicited by LPI (10 μM) in PAG neurons in the absence and in the presence of GPR55 antagonist ML-193 (10 μM). (B) [Ca2+]i elevations induced by LPI (0.1, 1, and 10 μM) alone and by LPI (10 μM) in the presence of ML-193 (10 μM); P < 0.00001 compared with basal (*), to any other concentration of LPI (**), or to 10 μM LPI (#). (C) Representative images indicating changes in Fura-2 AM fluorescence ratio (340/380 nm) of PAG neurons before and after LPI (10 μM) administration, in absence and presence of ML-193 (10 μM); hot colors indicate significant increases in [Ca2+]i. (D) Relative expression (log10) of GPR55 mRNA in rat brain cortex (tissue with a known high level of GPR55) and PAG.

Article Snippet: ML-193 (CID 1261822), N -(4-( N -(3,4-dimethylisoxazol-5-yl)sulfamoyl)-phenyl)-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide, was obtained from MolPort (Riga, Latvia). trans -Ned-19 was obtained from Tocris Biosciences (R&D Systems, Minneapolis, MN); ryanodine and xestospongin C were from EMD Millipore (Billerica, MA).

Techniques: Concentration Assay, Fluorescence, Expressing

Journal: Molecular Pharmacology

Article Title: The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray

doi: 10.1124/mol.115.099333

Figure Lengend Snippet: GPR55 mediates the effects of LPI and ML-193. (A) Representative recordings of the Ca2+ responses elicited by LPI (10 μM), ML-193 (10 μM), and by LPI in presence of ML-193 (both 10 μM) in GPR55-U2OS cells and by LPI (10 μM) in untransfected U2OS. (B) Comparison of the responses elicited by treatments indicated in A; P < 0.05 compared with basal (**) or to LPI effect in GPR55-U2OS (*).

Article Snippet: ML-193 (CID 1261822), N -(4-( N -(3,4-dimethylisoxazol-5-yl)sulfamoyl)-phenyl)-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide, was obtained from MolPort (Riga, Latvia). trans -Ned-19 was obtained from Tocris Biosciences (R&D Systems, Minneapolis, MN); ryanodine and xestospongin C were from EMD Millipore (Billerica, MA).

Techniques:

Journal: Molecular Pharmacology

Article Title: The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray

doi: 10.1124/mol.115.099333

Figure Lengend Snippet: LPI depolarizes cultured PAG neurons via GPR55. (A) Characteristic recordings of membrane potential changes induced by LPI (10 μM) administration in naive PAG neurons and in PAG neurons pretreated with ML-193 (10 μM). (B) Concentration-dependent depolarizing effect of LPI (0.1, 1, and 10 μM) and lack of effect of LPI (10 μM) in neurons treated with ML-193 (10 μM); P < 0.00001 compared with basal (*), to any other concentration of LPI (**), or to 10 μM LPI (#).

Article Snippet: ML-193 (CID 1261822), N -(4-( N -(3,4-dimethylisoxazol-5-yl)sulfamoyl)-phenyl)-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide, was obtained from MolPort (Riga, Latvia). trans -Ned-19 was obtained from Tocris Biosciences (R&D Systems, Minneapolis, MN); ryanodine and xestospongin C were from EMD Millipore (Billerica, MA).

Techniques: Cell Culture, Concentration Assay

Journal: Molecular Pharmacology

Article Title: The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray

doi: 10.1124/mol.115.099333

Figure Lengend Snippet: Time course of GPR55-mediated effects on nociception in the hot-plate test. LPI (1 μg/0.5 μl) or an equivalent volume of vehicle was microinjected at time zero. ML-193 (1 μg/0.5 μl) was given 15 minutes before LPI. The nociceptive response is expressed as the mean ± S.E.M. in seconds (sec). N, number of rats. Mean response before injection was as follows: ● = 10.29 ± 0.5 seconds; ▪ = 10.78 ± 0.2 seconds; ▴ = 10.67 ± 0.20 seconds; and ▾=10. 84 ± 0.20 seconds. P < 0.05 (*) and P < 0.01 (**) compared with the corresponding time point of the vehicle + vehicle group (▾) or to ML193 + LPI group (▴).

Article Snippet: ML-193 (CID 1261822), N -(4-( N -(3,4-dimethylisoxazol-5-yl)sulfamoyl)-phenyl)-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide, was obtained from MolPort (Riga, Latvia). trans -Ned-19 was obtained from Tocris Biosciences (R&D Systems, Minneapolis, MN); ryanodine and xestospongin C were from EMD Millipore (Billerica, MA).

Techniques: Hot Plate Test, Injection